 WATERTOWN, Mass., Oct. 28, 2020 GLOBE NEWSWIRE -- Pandion Therapeutics, Inc. Nasdaq: PAND, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the presentation of preclinical data highlighting the potential of its modular biologics pipeline for the treatment of autoimmune diseases at the Federation of Clinical Immunology Societies FOCIS 2020 virtual annual meeting. 